Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Eribulin mesylate, marketed under the brand name Halaven, is a synthetic analog of halichondrin B, a marine-derived natural product originally isolated from the sponge *Halichondria okadai*. Its molecular formula is C36H58BrNO10S·CH4O3S, and it carries the CAS registry number 723992-37-0. This potent microtubule dynamics inhibitor functions by binding to the growing ends of microtubules, effectively suppressing their polymerization and promoting depolymerization. By disrupting the mitotic spindle assembly, eribulin arrests cancer cells in the G2/M phase of the cell cycle, ultimately triggering apoptosis through intrinsic pathways.
Clinically, eribulin has established itself as a critical therapeutic agent for specific malignancies. It received regulatory approval primarily for the treatment of metastatic breast cancer in patients who have previously received at least two chemotherapy regimens, including an anthracycline and a taxane, either alone or in combination with other agents. Additionally, it is indicated for unresectable locally advanced or metastatic liposarcoma, particularly for patients with well-differentiated or dedifferentiated subtypes who have already undergone prior systemic therapy. The drug demonstrates efficacy even in tumors that are resistant to other standard treatments, offering a valuable option for those with limited therapeutic alternatives.
The administration of eribulin is typically performed via intravenous infusion over three minutes on days 1 and 8 of a 21-day cycle. Common adverse effects include neutropenia, fatigue, peripheral neuropathy, anemia, and constipation. While generally well-tolerated compared to some cytotoxic counterparts, careful monitoring of blood counts and neurological status is essential during treatment. Eribulin represents a significant advancement in oncology, bridging the gap between natural product chemistry and modern targeted cancer therapy. Its unique mechanism of action provides a distinct advantage in treating aggressive sarcomas and refractory breast cancers, contributing meaningfully to improved survival outcomes in these challenging clinical scenarios. As research continues, its potential role in combination therapies and broader indications remains an active area of investigation within the global medical community.